Results 21 to 30 of about 2,036 (191)

Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States [PDF]

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) causes a significant hospitalization burden in infants. The objective of this study was to evaluate the cost-effectiveness of introducing clesrovimab, a recently approved long-acting monoclonal ...
Klodeta Kura, John C. Lang, Dawei Wang, Yoonyoung Choi, Michelle G. Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H. Elbasha   +7 more
doaj   +2 more sources

Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study [PDF]

Infectious Diseases and Therapy
Introduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade, Erin Quinn, Lea J. Bayer, Amy W. Law, Christof von Eiff, Julia Schiffner-Rohe, Mark Atwood, Bennet Huebbe, Ahuva Averin   +8 more
doaj   +2 more sources

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Pathogens
Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV
Amanda Leach, Robert Kubiak, Tonya Villafana   +2 more
exaly   +3 more sources

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study [PDF]

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +2 more sources

Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Vaccines
Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age.
Camino Trobajo-Sanmartín, Manuel Garcia Cenoz, Juan Carlos Muruzábal Torquemada   +2 more
exaly   +3 more sources

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy [PDF]

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +2 more sources

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection [PDF]

Frontiers in Immunology, 2023
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly   +9 more
doaj   +2 more sources

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months [PDF]

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +2 more sources

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
Importance New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.
Lenglart, Lea, Levy, Corinne, Basmaci, Romain, Levieux, Karine, Kramer, Rolf, de Mari, Pauline, Béchet, Stéphane, Launay, Elise, Perceval, Lise, Cohen, Laure, Aupiais, Camille, de Pontual, Loic, Rybak, Alexis, Ouldali, Naim, Cohen, Robert   +14 more
openaire   +4 more sources

Efectividad de la inmunización con nirsevimab en neonatos para prevenir hospitalizaciones por virus respiratorio sincitial durante dos temporadas en Navarra [PDF]

Anales del Sistema Sanitario de Navarra
Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano, Ana Navascués, Leticia Armendáriz, Natividad Viguria, Mercedes Herranz-Aguirre, Manuel García Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, Iván Martínez-Baz, Carmen Ezpeleta, Guillermo Ezpeleta, Jesús Castilla   +11 more
doaj   +3 more sources